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Background: Inherited epidermolysis bullosa (EB) comprises a highly heterogeneous group of rare diseases characterized
by fragility and blistering of skin and mucous membranes. Clinical features combined with immunofluorescence antigen
mapping and/or electron microscopy examination of a skin biopsy allow to define the EB type and subtype. Molecular
diagnosis is nowadays feasible in all EB subtypes and required for prenatal diagnosis. The extent of skin and mucosal
lesions varies greatly depending on EB subtype and patient age. In the more severe EB subtypes lifelong generalized
blistering, chronic ulcerations and scarring sequelae lead to multiorgan involvement, major morbidity and life-threatening
complications. In the absence of a cure, patient management remains based on preventive measures, together with
symptomatic treatment of cutaneous and extracutaneous manifestations and complications. The rarity and complexity of
EB challenge its appropriate care. Thus, the aim of the present study has been to generate multicentre, multidisciplinary
recommendations on global skin care addressed to physicians, nurses and other health professionals dealing with EB,
both in centres of expertise and primary care setting.
Methods: Almost no controlled trials for EB treatment have been performed to date. For this reason, recommendations
were prepared by a multidisciplinary team of experts from different European EB centres based on available literature and
expert opinion. They have been subsequently revised by a panel of external experts, using an online-modified Delphi
method to generate consensus.
Results: Recommendations are reported according to the age of the patients. The major topics treated comprise the
multidisciplinary approach to EB patients, global skin care including wound care, management of itching and pain, and
early diagnosis of squamous cell carcinoma. Aspects of therapeutic patient education, care of disease burden and
continuity of care are also developed.
Conclusion: The recommendations are expected to be useful for daily global care of EB patients, in particular in the
community setting. An optimal management of patients is also a prerequisite to allow them to benefit from the specific
molecular and cell-based treatments currently under development.
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Inherited epidermolysis bullosa (EB) refers to a clinically
and genetically heterogeneous group of rare disorders
characterized by fragility of the skin and mucous mem-
branes. Based on the site of blister formation, four major
types of EB are currently distinguished: EB simplex
(EBS), junctional EB (JEB), dystrophic EB (DEB), and
Kindler syndrome (KS); each one is then subdivided into
several subtypes based on the mode of transmission and
a combination of phenotypic, immunofluorescence, ul-
trastructural and molecular findings [1]. Once the cleav-
age level and protein expression pattern has been
determined, molecular testing is the most accurate diag-
nostic procedure for EB subtype definition. Furthermore,
it is required for DNA-based prenatal diagnosis. The ex-
tent and severity of skin and mucous membrane lesions
and multiorgan involvement vary markedly in the differ-
ent EB types and subtypes and in relation to age [1-5].
In several EB subtypes, the cutaneous and extracuta-
neous manifestations and complications lead to a signifi-
cant morbidity and even to premature death. The rarity
of EB and the phenotypic variability challenge the appro-
priate care of these patients.
Despite the preclinical development of different molecu-
lar and cell-based treatment strategies, no cure is still avail-
able for EB [6]. In the absence of a specific therapy, patient
management is currently centered on preventive and skin
care measures, and early recognition and symptomatic
treatment of complications. As almost no controlled trials
for EB treatment have been performed to date [7], mea-
sures for EB management mainly rely on the experience of
physicians, nurses and other involved healthcare profes-
sionals. The development of consensus recommendations
based on literature data and shared expertise among ex-
perts from different countries represents an important step
towards improved standard of care and quality of life for af-
fected patients and their caregivers. Consensus recommen-
dations based on best evidence available have been recently
generated by an international panel of EB experts [8]. They
comprise 17 items centered on wound care and related
general health and patient issues. In addition, comprehen-
sive best practice guidelines addressing all aspects of oral
health care in EB have been published [9]. Finally, guide-
lines for wound and skin care in the major EB types have
been generated by clinical experts and made available on
the Debra International website [10]. These documents
provide an invaluable support for the treatment of specific
and major manifestations of EB disease. However, they
do not address several equally important disease-related
aspects such as the multidisciplinary management
organization, therapeutic patient education, care of dis-
ease burden and continuity of care. We have therefore
developed a list of consensus recommendations on
current best practices for global skin care in EB. Theyare conceived to provide a practical support for day-to-
day management of patients both in a hospital setting
and in community care. Our aim has been to consider
all aspects of patient life affected by the skin disease and
also the family burden. The recommendations are ad-
dressed to all healthcare professionals dealing with EB
both in centres of expertise and in community care: physi-
cians (dermatologists, neonatologists, pediatricians, inter-
nists, pain relief doctors, anesthetists, surgeons, general
practitioners), nurses, dieticians, psychologists, physical and
occupational therapists, and social workers. They are ex-
pected to be useful also for patients and their caregivers.
Methods
A multidisciplinary group of experts in EB diagnosis and
care from different European countries (France, Italy and
Portugal) met in Paris in October 2011 at the occasion of
the closing meeting of the EU-supported project “Together
Against Genodermatoses”. It was decided to generate a list
of consensus recommendations on current best practices
for global skin care in patients affected with all types of EB.
A list of topics was identified and subgroups of experts re-
vised the pertinent literature (English, French and Italian)
since January 2000. Older articles deemed relevant by the
experts were also considered. Literature search included all
published recommendations and guidelines on EB care. A
provisional list of recommendations for each topic was then
prepared. The resulting global document was revised by
additional experts from Spain and Slovenia and then circu-
lated among a second group of experts using an online-
modified Delphi method to generate consensus. The final
document is reported below.
Multidisciplinary management of EB patients
The fragility of the skin and mucous membranes in EB
patients results in the involvement of many organs and
systems [1-5,11-18] (Tables 1 and 2). In addition, disease
manifestations vary upon the age of the patients and the
EB type and subtype.
General principles
 Treatment of EB patients should be performed in
centres of expertise adhering to the
recommendations for quality criteria issued by the
European Union Committee of Experts on Rare
Diseases (EUCERD) [19].
 Centres of expertise should also guarantee the
continuity of care between pediatric age and
adulthood [20].
 A coordinated multidisciplinary approach must be
adopted (Table 3).
 The coordinator of the team should be a
dermatologist in order to ensure both an integrated
Table 1 Major epidermolysis bullosa complications affecting the skin, eye and ENT area
Tissue/organ/system Major complications EB type/subtype*
Skin Fluid loss Lethal acantholytic EB, JEB-H, EBS-PA, JEB-PA
Chronic/infected wounds RDEB-SG, RDEB-I, RDEB-O, JEB-H, JEB-nH, EBS-AR, DEB-Pr,
DDEB-G, EBS-DM
Exuberant granulation tissue LOC, JEB-H, JEB-nH
Atrophic scars, post-inflammatory pigmentary changes DEB, JEB, EBS
Poikiloderma/diffuse skin atrophy KS
Excessive/hypertrophic scarring RDEB-SG, RDEB-I, DEB-Pt, DEB-Pr, RDEB-O
Albopapuloid lesions DEB
Milia DEB, JEB, EBS, KS
Palmoplantar keratoderma EBS, JEB-nH, KS
Aplasia cutis congenita EBS-PA, JEB-PA, DEB, other JEB and EBS subtypes
EB nevi JEB, DEB, EBS
Basal cell carcinomas EBS-DM
Squamous cell carcinomas RDEB-SG, RDEB-O, KS, JEB-nH, RDEB-I
Skin adnexa Onychodystrophy, nail shedding or loss DEB, JEB, EBS-MD, EBS-DM, EBS-PD, EBS-AR, EBS-O, KS
Scarring alopecia JEB-nH, RDEB-SG, JEB-H, JEB-PA, RDEB-O
Alopecia universalis Lethal acantholytic EB
Hypotrichosis EBS-PD
Oral cavity Microstomia, ankyloglossia, obliteration of the oral vestibules RDEB-SG, RDEB-I, RDEB-O
Enamel hypoplasia JEB, EBS-MD
Multiple caries and tooth decay DEB, JEB
Periodontitis KS
External eye Corneal erosions RDEB-SG, JEB-H, RDEB-O, RDEB-I, JEB-nH, EBS-DM, KS
Blepharitis, corneal scarring and/or pannus formation RDEB-SG, RDEB-I, JEB-H, RDEB-O, JEB-nH
Symblepharon LOC, RDEB-SG, RDEB-I, JEB-H, JEB-nH
Ectropion/exposure keratitis JEB-H, RDEB-SG, KS
Diminished vision/blindness RDEB-SG
Conjunctival granulation tissue LOC
External ear External auditory canal narrowing/conductive hearing loss RDEB-I
Nose Nare narrowing (granulation tissue) JEB-H, JEB-nH, LOC
*The epidermolysis bullosa (EB) types and subtypes which present a higher frequency of a given complication are listed first.
EBS, epidermolysis bullosa simplex; EBS-PA, EBS with pyloric atresia; EBS-DM, EBS, Dowling-Meara; EBS-MD, EBS with muscular dystrophy; EBS-AR, EBS, autosomal
recessive; EBS-PD, plakophilin deficiency; EBS-O, EBS, generalized other; JEB, junctional epidermolysis bullosa; JEB-H, JEB, Herlitz; JEB-nH, JEB, non-Herlitz; JEB-PA,
JEB with pyloric atresia; LOC, laryngo-onycho-cutaneous syndrome; DEB, dystrophic epidermolysis bullosa; DDEB, dominant DEB; DDEB-G, DDEB, generalized; RDEB-SG,
recessive DEB, severe generalized; RDEB-O, recessive DEB, generalized other; RDEB-I, recessive DEB, inversa; DEB-Pr, DEB, pruriginosa; DEB-Pt, pretibial DEB; KS, Kindler
syndrome.
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community healthcare system [21-30].
 The multidisciplinary management is centered on
the patient; therefore, it is a tailored treatment for
each patient.
 The multidisciplinary team should be specifically
trained and regularly updated [19].
Care of the EB newborn and infant
Several procedures performed in newborns and infants
can severely injury the EB fragile skin and require spe-
cific and adapted care measures [10,31,32]. In addition,the skin immaturity in pre-term newborns affected
with EB and the ongoing functional skin adaptation to
the extra-uterine environment in term babies demand
particular caution in skin handling and care. Skin and
mucosal lesions predispose to recurrent and potentially
life-threatening infections and cause loss of fluids and
electrolytes which can lead to dehydration and electro-
lyte imbalance. Although the extent and severity of
skin and mucous membrane involvement is extremely
variable, general and specific measures for skin care of
the newborn and infant affected with EB can be
recommended.
Table 2 Other major extracutaneous complications of epidermolysis bullosa
Tissue/organ/system Major complications EB type/subtype*
Gastrointestinal tract Pyloric atresia JEB-PA, EBS-PA
Esophageal stenosis/strictures/web formation RDEB-SG, RDEB-I, KS, RDEB-O
Chronic constipation/fecal impaction RDEB-SG, RDEB-I, RDEB-O, DDEB, JEB-H, JEB-nH, EBS-DM, EBS-MD
Gastroesophageal reflux disease RDEB, JEB-nH, EBS-DM, EBS-MD, JEB-PA, JEB-H, DDEB
Anal fissures/stenosis RDEB-SG, RDEB-I, RBED-O, KS
Protein-loosing enteropathy JEB-PA, EBS-PA, JEB-H, JEB-nH
Colitis/diarrhea KS, RDEB, JEB-PA
Genitourinary tract Urethral strictures, meatal stenosis JEB-H, RDEB-SG, JEB-PA, JEB-nH, LOC, KS
Genitourinary malformations, ureteral/ureterovesical
junction obstruction/stenosis, recurrent cystitis
JEB-PA, EBS-PA
Vulvar/vaginal scarring/strictures RDEB-I, KS
Renal failure RDEB-SG, JEB-PA, JEB-nH
Upper respiratory tract Tracheolaryngeal stenosis/acute respiratory failure JEB-H, LOC, EBS-MD, lethal acantholytic EB, EBS-DM
Musculoskeletal system Osteopenia and osteoporosis RDEB-SG, RDEB-O, JEB-nH
Limb flexion contractures RDEB-SG
Digit contractures/pseudosyndactyly RDEB-SG, RDEB-O, RDEB-I, KS
Mitten deformities RDEB-SG
Muscular dystrophy EBS-MD, EBS-PA
Hematopoietic system Multifactorial anemia RDEB-SG, JEB-H, JEB-PA, EBS-PA, JEB-nH, EBS-AR, EBS-DM, RDEB-O
Heart Dilated cardiomyopathy RDEB-SG, JEB-nH, EBS-MD
Endocrine Delayed puberty, amenorrhea RDEB-SG, RDEB-O
Systemic complications Sepsis JEB-H, JEB-nH, RDEB-SG, EBS-DM
Failure to thrive, growth retardation JEB-H, JEB-PA, EBS-PA, RDEB-SG, JEB-nH, RDEB-O, EBS-AR,
EBS-DM, RDEB-I
*The EB types and subtypes which present a higher frequency of a given complication are listed first.
EBS, epidermolysis bullosa simplex; EBS-PA, EBS with pyloric atresia; EBS-DM, EBS, Dowling-Meara; EBS-MD, EBS with muscular dystrophy; EBS-AR, EBS, autosomal recessive;
EBS-PD, plakophilin deficiency; EBS-O, EBS, generalized other; JEB, junctional epidermolysis bullosa; JEB-H, JEB, Herlitz; JEB-nH, JEB, non-Herlitz; JEB-PA, JEB with pyloric atresia;
LOC, laryngo-onycho-cutaneous syndrome; DEB, dystrophic epidermolysis bullosa; DDEB, dominant DEB; DDEB-G, DDEB, generalized; RDEB,recessive DEB; RDEB-SG, recessive
DEB, severe generalized; RDEB-O, recessive DEB, generalized other; RDEB-I, recessive DEB, inversa; DEB-Pr, DEB, pruriginosa; DEB-Pt, pretibial DEB; KS, Kindler syndrome.
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 The first multidisciplinary care should be provided
independently from the diagnostic definition of the
EB type and subtype.
 Diagnosis should be performed as soon as possible
in order to implement the most appropriate
treatment, communicate the diagnosis and specific
information to the parents. Methods and criteria for
diagnosis have been regularly updated by an
International Consensus Conference [1].
 The communication of the diagnosis should involve
the dermatologist and the neonatologist and should
be addressed to both parents. The information
should be delivered gradually and adapted to the
family socio-cultural level.
 A psychologist should support the family (see
paragraph “Care of disease burden”).
 Caregiver education should start promptly (see
paragraph “Therapeutic patient education”). Members of the multidisciplinary team usually
involved in EB care in infancy are neonatologist/
pediatrician, dermatologist, anesthetist, pathologist,
medical geneticist, psychologist and specialized
nurses.
General measures
 Blood sampling for complete blood count,
electrolytes, C-reactive protein, urea, creatinine,
total serum protein and albumin, iron, zinc,
and, whenever required, blood cultures. Swabs
for culture should be taken from infected
wounds.
 In severely affected newborns, a venous access
should be guaranteed through placement of an
umbilical venous catheter. Whenever required, this
will be followed by elective insertion of an
indwelling central venous catheter (tunnelled
external design such as Broviac catheters).
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prevent blistering:✓ the baby should not be placed systematically in an
incubator unless needed for reasons such as
prematurity [10]: heat and humidity can lower the
threshold for blistering. An overhead heater can be
used, cautiously regulated.
✓ Naso- and oro-pharyngeal suction should be
avoided. If required, a soft catheter is chosen, and
minimal suction pressure exerted [31].
✓ The umbilical cord should be secured with a
ligature, avoiding the use of plastic clamps which
rub the skin [10,31].
✓ The use of clips should be avoided, and name
band put on clothing instead of wrist.
✓ Electrodes should be of small size; the adhesive
rim should be removed allowing only the
lubricated central portion to be in contact with the
skin and the electrode should then be secured with
a non-adhesive dressing
(e.g. Mepilex®, Mölnlycke) [33].
✓ Clip sensors should be used for pulse oximetry.
✓ For blood pressure monitoring, thick padding is
recommended before applying the blood pressure
cuff.✓ When possible, skin-to-skin contact (kangaroo
care) with parents should be encouraged.
✓ There is no contraindication to immunization for
infectious diseases.
Skin care
 For clothing, a front-fastening babygro is easier to
put on and remove. It should be turned inside out
to prevent the seams from rubbing skin [31]. If
available, DermaSilk® (Alpretec) underclothes and
gloves can be used as they combine silk properties
with the protective activity of an antimicrobial agent,
in addition to being seam-free. Alternatively, Tubifast
(Mölnlycke) garments and gloves can be used [10].
 Disposable nappies can be used, they should first be
lined with a soft material (e.g. soft silicone contact layer
or foam such as Mepitac®, Mölnlycke) in order to
reduce skin rubbing from the elastic edges. Nappies
with Velcro fasteners prove safer as it is less likely for
the securing tapes to adhere to the skin [10,31].
 Particular attention should be paid to avoid friction
when handling the baby: he/she should be nursed on
neonatal incubator mattress, and lifted by sliding hands
below the mattress or using the sheet [10]. To handle
the naked infant, the nurse/caregiver should roll the
baby away, place one hand behind his/her neck and
head and the other one behind his/her buttocks, let the
baby roll back and then lift him/her [31,32] (Figure 1).
 Adhesive tapes must be avoided. Soft silicone fixation
tapes providing atraumatic removal (e.g. Mepitac®) are
recommended to secure devices such as electrodes,
catheters, tubes, and probes. For removal they should
be rolled out gently rather than lifted.
 Silicone Medical Adhesive Removers (SMARs), such
as Appeel® (CliniMed) or Niltac®, should be used to
remove electrodes or accidentally applied tapes or
dressing/clothing adhered to wounds. If SMARs are
not available, liquid and white soft paraffin in equal
parts facilitate atraumatic removal [10,34,35].
 Regular bathing in tepid to slightly warm water is
recommended (Figure 1), the frequency will be
adapted to each case. If the infant presents crusted
lesions, an emollient/oil-based cleanser should be
used, while infected wounds should be treated with
an antiseptic (e.g. containing 0.1% chlorhexidine).
After bathing, the skin should be dried by gentle
padding with a towel.
 Diaper area cleansing should be performed with
liquid and white soft paraffin in equal parts or with
an emollient/oil-based cleanser [10,31].
 Principles for blister, aplasia cutis congenita and
wound treatment are similar to those applying to
children and adults (see paragraph “Wound care”).
Figure 1 Inherited epidermolysis bullosa: wound care. (a, b) Dressing cart prepared in advance for patient dressing: soft silicone foams (*),
petroleum jelly (<), emollient cream (>), antimicrobial cream (◊), gauzes, tubular bandages, needles and swabs for culture (∇). (c) How to hold the
baby: one hand behind the head and the other one behind the buttocks. (d) Bathing the baby also facilitates atraumatic removal of dressings
which float into the water. (e-h) Wound care with non-adherent soft silicone dressings and thin polyurethane-soft silicone foams. (i) Lancing and
draining of a haemorrhagic blister. (j-k) Soft silicone foams specifically modelled for hand dressing (j), and hand dressing to separate fingers and
prevent early digit fusion (k).
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or feet or digit degloving following delivery require
specific dressing in order to prevent early digit fusion
[10]. The separation should be performed by using
easily modelled dressings, such as soft silicone foams
(e.g. Mepilex® or Mepilex Lite®), which are cut into
strips (Figure 1). If advanced dressings are not
available, paraffin-impregnated gauzes can be used,
and should also be cut into thin strips. Attention
should be paid to keep the first finger extended and
separated from the rest of the hand.
 The diaper area is constantly subject to handling,
exposed to urine, feces and to the diaper occlusion
effect. We prefer to treat the less exuding erosions
with paraffin-impregnated gauzes, replaced at each
nappy change. Alternatively, a soft silicone primary
wound dressing (e.g. Mepitel®) or hydrogel-impregnated gauzes (e.g. Intrasite® Conformable,
Smith & Nephew) can be used. In more exuding
lesions, an antiseptic and silicone foams (e.g.
Mepilex® or Mepilex®Transfer) are indicated.
Feeding modalities
 In less severely affected newborns breast-feeding is
possible: soft paraffin can be applied on the nipple
and breast as well as on the infant face and lips to
reduce friction from rooting reflex [31]. The mother
should be trained to handle the baby and breast feed
him. When breast-feeding proves traumatic, oral
feeding remains the best option, also allowing to add
supplements in malnourished infants.
 Commercially available teats should be softened with
warm boiled water. The teat hole can be enlarged or
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can be protected with petroleum jelly to avoid the skin
sticking to the teat [31].
 A Haberman feeder reduces the sucking effort and
its long teat avoids nose trauma from the bottle
collar [10,31].
 A few infants may require naso-gastric feeding.
A small soft polyurethane tube fixed for few weeks
will minimize internal damage and reduce the
trauma [31].
 For nutritional principles see paragraph “Nutritional
aspects”.
Follow-up
 The infant should be discharged home when the
general health condition is stable and the parents are
adequately educated and confident to care for their
baby. This decision is taken jointly by the dermatologist
and neonatologist/pediatrician. The involvement of
social workers and psychologists in the organization of
the discharge is helpful.
 A first follow-up visit with a specialized team
(usually: dermatologist, pediatrician, EB nurse,
psychologist) will be organized in one or two weeks
for severe EB subtypes (e.g. Dowling-Meara EBS,
JEB and recessive DEB). It should comprise a
complete clinical examination (skin/mucosae,
nutrition, pain, etc.), dressing, and evaluate and
pursue the therapeutic education of the parents. If
the infant care is correctly performed the next
appointment should be in one month, then every
three months during infancy. In mild EB subtypes
the follow-up visits will be every 3–6 months.
EB care from childhood to adult
Additional problems in skin and wound management
during childhood to adulthood include, in particular in
Dowling-Meara EBS, generalized forms of JEB and re-
cessive DEB (RDEB) [4,5,12,13,17,36-38]:
 reduced patient compliance to care and claim for
self-care;
 chronic pain;
 presence of chronic wounds and their susceptibility
to infection;
 risk of cancer development;
 chronic itching;
 anemia and malnutrition secondary to oral and
gastrointestinal involvement and chronic wounds,
in turn negatively interfering with wound healing;
 psychological problems related to both disease
acceptance and social relationship (school, hobbies,
job, etc.).General principles
 The members of multidisciplinary team vary upon
the EB type and patient and family needs. In mild
EBS subtypes (e.g. localized and generalized non-
Dowling-Meara EBS), the dermatologist ensures the
follow-up with the help of a specialized nurse. In
severe EBS forms (such as Dowling-Meara EBS or
EBS with muscular dystrophy), JEB and generalized
DEB subtypes the core members are the
dermatologist and the pediatrician supported by the
EB nurse and dietician. Other specialists
(ophthalmologist, dentist, digestive surgeon,
psychologist, physiotherapists, etc.) are involved
depending on disease complications.
 A regular follow-up is required to evaluate skin
and mucosal conditions, general health status, and
specific problems encountered by the patient and
his/her caregivers. Follow-up planning should be
performed taking into account the EB type,
disease complications, family and patient
compliance and specific complains. After
childhood, EBS and mild DEB patients are
generally seen by an EB specialist once a year;
JEB and generalized RDEB should be seen at least
twice a year. More frequent follow-up visits (e.g.
every month) are required for the most severe
patients in order to fasten wound healing and
to early diagnose and treat squamous cell
carcinoma.
General measures
 Monitoring of severe EBS variants (e.g. Dowling-
Meara EBS or EBS with muscular dystrophy), JEB,
and generalized RDEB subtypes comprises at follow-
up visits: a complete blood count, electrolytes, total
serum protein and albumin, iron, iron-binding
capacity, ferritin, erythrocyte sedimentation rate, C-
reactive protein, liver function tests, urea, creatinine
and, if required, zinc, selenium, folate and vitamins
(A, B6, C, D and E) [22,39]. Swabs for culture should
be taken from infected and critically colonized
wounds, as blood cultures in case of sepsis
suspicion.
 Patient adherence to therapy should be regularly
checked. Caregiver and patient compliance and
experience should be always taken into account in
designing the care plan.
 Immunization schedule for infectious diseases
should be regularly continued. Chicken pox
vaccination is recommended.
 Preventive measures to reduce the onset of new
lesions are summarized in Table 4 [10,31,32,40].
Table 4 Preventive measures to reduce the onset of new lesions during daily life
Direct skin protection • Protect vulnerable skin sites, (e.g. knees and elbows) with soft silicon contact layers, silicon sheets or strips (e.g. KerraPro®)
or thick padding
• Use gloves when the child begins to crawl/walk and lifelong during sports or hobbies (e.g. DermaSilk® or Tubifast®)
• Avoid hard shoes with internal seams, tight clothes and clothes with raised seams, tags in contact with the skin
• Use protective padding for shoes, such as a poron insole or orthotic device
• Pad the frame at the nose bridge and over the ears of eye glasses
Other measures • Ensure that toys are frequently cleaned and in soft material without traumatic angles
• Prefer hobbies and sports at low risk of skin trauma (e.g. adapted gym, swimming, ping-pong, reading, singing, playing
music, electronic toys and informatics)
• House air conditioning and other cooling measures in hot climates
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 Regular patient follow-up by the dermatologist
comprises the assessment of the entire body
including the scalp, external ear, genital/anal area,
oral cavity and nostrils.
 A dermatological management is necessary in all
types of EB and skin lesions.
 An appropriate analgesia should be performed
before any procedure, such as bathing or dressing
(see paragraph “Pain management”).
 For the hygiene, a mild antiseptic cleanser (e.g.
chlorhexidine 0.1% or polyhexanide, sodium
hypochlorite 5–10 ml in 5 L of water, acetic
acid ≤0.25%) should be used for extended and/or
critically colonized/infected lesions [39,41]. An
emollient/oil-based cleanser should be chosen
for xerotic skin and hyperkeratotic or crusted
lesions.
 Bathing frequency depends on the type of dressing
and lesion characteristics: in case of infected wounds
or dressings which stick to the lesions (e.g. paraffin-
impregnated gauzes) bathing should be performed
every other day; when advanced dressings are
employed bathing can be delayed until once a week.
 New blisters should be lanced (finger prick lancet,
sterile large-bore needle or scalpel blade) (Figure 1)
and drained. The blister roof should be left in place
to facilitate re-epithelialization, to reduce infection
risk and pain [10,31,32,42].
 Daily use of emollients and moisturizing products is
strongly recommended for xerotic skin in order to
reduce blistering, pain and itching [31].
 Regular photoprotection is mandatory in patients
affected by KS who present photosensitivity.
 Courses of topical keratolytic agents (e.g. urea,
salicylic acid, ammonium lactate) are helpful to treat
palmoplantar hyperkeratosis and/or keratoderma
[40]. Their concentration depends on the patient
age, rhythm of application, treatment duration andlocal tolerance. Particular caution is required for
young children.
 Hyperhidrosis, frequent in EBS patients, should be
treated in order to reduce/prevent blistering and
itching. Corn flour is an inexpensive and easily
available remedy [10,40], other absorbent powders
(e.g. Zeasorb®, Stiefel Laboratories) may also be
useful. An additional option is iontophoresis [43].
Furthermore, the use of botulinum toxin may be
considered for severe plantar hyperhidrosis [43,44].
Silver-lined or Dermasilk socks keep feet dry and
comfy, provide anti-friction action and reduce the
risk of bacterial overgrowth [10,40].
 EB nevi should undergo a regular clinical and
dermoscopic follow-up [11]. Although a slightly
increased risk of melanoma has been reported only
for RDEB, atypical pigmented lesions undergoing
significant morphological changes should be
biopsied [45 and references herein].
 No specific treatment is required for milia.
 Mucosal care:
 Oral management should adhere to the recently
published best practice guidelines for oral health
care in EB [9].
 Conjunctiva should be regularly lubricated, in
particular in JEB or RDEB patients, with lanolin
and preservative-free eye drops or gels, e.g.
containing hyaluronic acid, polyethylene/
propylene glycol or carbomer [45].
 Nasal lubricants are more frequently indicated for
JEB or RDEB patients; regular ointment
containing vitamin E or simply petroleum jelly
can be helpful.
Wound care
The choice of dressings varies upon the type and site of
the lesions, but also product availability [8,10,42,46,47].
Advanced dressings delay the frequency of dressing
change, thus reducing pain and manipulation-related
risk of blistering and infections. In addition, non-
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dressing removal. However, systematic literature reviews
showed only a modest advantage for advanced dressings
(e.g. hydrogels, hydrofibers and foams) compared to
paraffin-impregnated gauzes in accelerating healing of
non-EB chronic wounds (venous leg ulcers, pressure
sores, etc.) [48]. As to topical antibiotics and antiseptics,
their role in healing of leg ulcers remains to be proved
[49]; there is a good evidence of their usefulness for the
treatment of superficial skin infections [50]. The de-
bridement of the wounds is important to accelerate the
healing process and to prevent infection: some dressings
such as hydrogels, polymeric membranes and hydrofi-
bers are helpful [8,10,46,47]. In case of multiple and
deep necrotic lesions, mechanical debridement should
be performed gently in the theatre with analgesia.
Dry to lightly exuding wounds
 Non adhesive soft silicone or lipido-colloid contact
layers [e.g. Mepitel®, Adaptic® touch (Systagenix),
Urgotul® (Urgo Medical), Silflex® (Advancis Medical)],
thin polyurethane-soft silicone foams (e.g. Mepilex®
Lite), and hydrogels (e.g. Intrasite® Conformable)
appear to be the most suitable in these lesions
[8,10,46,51]. Hydrogel dressings should be changed
daily or as soon as they become dry. The other types
could be changed every 3–4 days.
 The dressing choice depends on the affected site:
e.g. flexible dressings should be used mainly for
the folds. Soft bordered materials [e.g. Mepilex®
Border, Alleyvn® Gentle Border (Smith &
Nephew)] easily adapt to the different skin sites
but they may be too sticky and thus require a
primary contact layer in order to protect fragile
skin [10].
Heavy exuding wounds
 Heavy exuding wounds present a high risk of
infection and require specific dressings. Either
hydrofiber dressings (e.g. Aquacel®, Convatec) or
soft silicone foam with super-absorbers (e.g.
Cutimed® Siltec, BSNmedical), able to absorb the
abundant exudates, should be preferred. Soft
silicone foams [e.g. Mepilex®, Mepilex® Transfer, and
Advazorb Silflo® (Advancis Medical)] and polymeric
membranes (PolyMem®, Ferris Mfg. Corp.) are also
indicated [8,10,46,51]. The soft silicone foams are
also suited for digits and folds. On the other hand,
PolyMem® is not easily retained on the wounds and
requires a secondary dressing to hold in place. Also
Mepilex® Transfer needs a secondary dressing to
absorb exudates.Critically colonized and infected wounds
 To early diagnose a critically colonized or infected
wound the following parameters and features should
be considered:
✓ wound history: several week duration, recent size
extension and exudate increase;
✓ wound bed: presence of debris, dead slough,
friable tissue and bad smelling;
✓ wound margins and surrounding skin: oedema,
erythema, higher temperature than the healthy
skin.
 In the presence of the above mentioned criteria,
swabs for culture should be taken after washing
the lesion with normal saline and then the
treatment should be started based on clinical
features [41].
 Wounds should be cleaned with mild antiseptics,
such as chlorhexidine 0.1% or polyhexanide,
sodium hypochlorite at a concentration of 5–10
ml in 5 liters of water, or acetic acid at ≤0.25%
for 15–20 minutes/day [39,41].
 In case of lesions at risk of infection, the use of
lipid-stabilized hydrogen peroxide cream
(Crystacide®) has been proposed [41]. An aqueous
solution of eosin (2%) is employed in some
countries with the aim to reduce the exudate,
keeping in mind that it has no antiseptic
properties. In other countries, medical-grade
honey in ointments (e.g. Mesitran S®, Medloc) or
dressings (e.g. Algivon®, Advancis Medical;
Medihoney®, Derma Sciences) are available
and used with the aim to reduce the risk of
infection and promote wound debridement
[10,41,52,53].
 The use of silver-containing creams (e.g. silver
sulfadiazine) or dressings (e.g. Mepilex®AG;
Urgotul®silver/SSD; PolyMem®silver, Aquacel®Ag)
has been advocated [10,41]. However, there is no
clear evidence that silver-containing products can
prevent wound infection or improve healing rates
of leg ulcers [52 and references herein].
Importantly, silver plasma level should be checked
in case of large surface and/or prolonged treatment
because of the risk of silver absorption and related
toxicity [54,55]. In children, the use of silver-
containing products should be very limited in time
and treated surface.
 The dressings for infected wounds are the same
used for heavy exuding wounds, but they should
be changed daily.
 Principles for the use of topical and systemic
antibiotics/antimicrobials are summarized in Table 5
[8,41,56].
Table 5 Principles for use of antibiotics/antimicrobials in
wound treatment
Topical agents • Restrict the use to critically colonized and infected
wounds
• Prefer agents which do not have a systemic
formulation (e.g. fusidic acid, mupirocin)
• Use for short periods and rotate to avoid
resistances and sensitizations
• Consider retapamulin as a second line treatment
for resistant Gram positive bacteria
Systemic agents • Administer in multiple infected lesions
• Start early in malnourished and/or non compliant
patients and in infants
• Prescribe antibiotics according to the result
of culture
• Prefer narrow spectrum antibiotics
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 Warty and crusted lesions require an accurate
treatment and follow-up because they are itchy and
can mask an underlying squamous cell carcinoma.
The crusts and hyperkeratosis should be regularly
removed. Frequent application of emollient creams
and bathing twice a week are indicated to this purpose.
Exuberant granulation tissue
 Short courses of very potent topical
glucocorticoid ointments are reported as effective
in reducing the exuberant granulation tissue
frequently observed in JEB [8,10].
General remarks
 The dressings of all types of wounds should be
checked daily and the change frequency modified
based on wetting and smelling.
 Paraffin-impregnated gauzes (e.g. Jelonet®, Smith &
Nephew) or medicated gauzes (e.g. Fitostimoline®
containing an aqueous extract of Triticum vulgaris,Table 6 Chronic itch management
General measures • Bathing in tepid water with syndet/oil cleanse
• Overheating and dry environment avoidance
• Relaxation techniques and patient education
Therapeutic options • Short courses of topical mid-potency steroids
• Sedating antihistamines (e.g. hydroxyzine) and
treatment*
• Low-dose gabapentin (Neurontin®) or pregab
• Anti-inflammatory agents (e.g. cyclosporine, th
treatment only in severe cases**
*Data from randomized trials are lacking to support the efficacy of antihistamines in
**Caution should be paid in using immunosuppressive drugs because of the carcinor Connectivine®, Fidia, containing hyaluronic acid)
can be used when advanced dressings are not
available [8,10]. They require a secondary dressing
and should be changed on a daily basis, increasing
wound manipulation, pain and indirectly also the
risk of infection. These products adhere to the
wound bed. In order to reduce pain and trauma,
dressing removal requires prolonged soaking with
distilled water or saline solution or bathing [8,10].
 In RDEB patients, finger and toe dressing should be
regularly performed as described for the neonatal
period, to delay digit fusion and pseudosyndactyly [10].
 Tubular bandages of various sizes and heights
according to the affected body area (e.g. Elastomul®,
Tubifast® or Self-fix®) should be used for dressing
retention to prevent slipping and further trauma.
Tight bandages must be avoided as they can induce
blistering by rubbing the skin [8,10]. If available,
Dermasilk® or other specifically designed garments,
without silver, can also be useful to retain the
dressings in place.
Itch management
Itching is common in EB patients with dry/atrophic skin,
multiple warty lesions, during late phase of wound heal-
ing, or following sensitization to topical treatment. Prur-
itus may also develop in the absence of an identifiable
etiology [8,10]. Itching is frequently chronic, severe and
unresponsive to conventional treatments. Furthermore, a
rare subtype of DEB, DEB pruriginosa, is characterized
by onset of severe and unremitting pruritus from infancy
to adulthood [57,58]. Itch-induced scratching damages
the skin, thus increasing blistering and susceptibility to
infection. General measures and therapeutic options to
manage itch are summarized in Table 6 [8,10,59-64].
Management for surgical procedures
General principles
 Surgery in general anaesthesia should be limited to
strictly necessary procedures and organized jointlyr and skin hydration with emollients
to cope with the vicious itch–scratch cycle
/or tricyclics with anti-H1 antihistaminic action (doxepin) as first-line
alin (Lyrica®) as second-line treatment
alidomide or topical tacrolimus) to be cautiously considered as third-line
pruritic conditions other than urticaria.
ogenesis risk.
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nurse) and the EB team coordinator.
 Whenever necessary and feasible, the different
surgical treatments should be performed at one time
in order to reduce the risks linked to anaesthesia.
 A tailored management should be planned for each
patient after a careful evaluation.
General measures
 When a surgical procedure in general anesthesia is
planned, a multidisciplinary re-assessment should be
performed a week or two ahead of the surgery date
to verify the general health conditions of the patient
[33].
 Blood sampling should be performed before surgery
to evaluate and treat anemia.
 Before the procedure, the surgical team, including
the anaesthesiologist and the case manager, should
clearly explain the possible problems and
complications linked to the procedure, paying
particular attention to those related to EB disease.Table 7 Patient management in the operating theater
Procedure Measures to be adopted
Operating table • Place an anti-decubitus mattress and cush
• Use the sheet to lift the infant and move
• Pad trauma-exposed sites (e.g. chin, occip
Premedication • Administer oral premedication 45 minutes
✓ Patient anxiety (midazolam 0.5 mg/kg)
✓ Oral secretion (atropine 40 mcg/kg)
✓ Gastro-esophageal reflux (ranitidine 1 mg
✓ Vomiting (metoclopramide 150 mcg/kg)
• Prefer intravenous induction in presence o
protect the face from the mask with silico
• Protect the eyes with a moisturizing opht
Patient monitoring • Use tape with a silicon contact layer (Mep
• Lubricate all tubes with a water-based lub
• Remove the adhesive part of electrodes a
then secure with a non adhesive dressing
• Use clip sensors for pulse oximetry
• Use a lubricated disposable thermometer
• Pad the skin with cotton or advanced dre
• Use bipolar diathermy to avoid a monopo
• Avoid carefully all kinds of trauma and fric
Intubation • Evaluate microstomia, esophageal stricture
• Prefer fiberoptic-assisted intubation to lary
Recovery room • Administer a moderate sedation before em
• Perform tracheal aspiration gently using s
*RDEB, recessive dystrophic epidermolysis bullosa.Specific measures
 Anxiolytic administration can be helpful in the pre-
operative stage.
 The measures to be adopted in the operating theatre
are summarized in Table 7 [33-66].
 After surgery, the intravenous line should be kept in
place as long as possible to be used for transfusion,
perfusion or other systemic therapy (iron, albumin,
antibiotics).
 Fiberoptic intubation appears to be a good
technique to minimise frictional trauma and to
reduce the risk of blistering, whilst safely securing
the difficult airway [67].
Pain management
Pain is constant in EB patients since birth, and its
management is a major therapeutic focus conditioning
the daily care. A tailored approach should be planned
for each patient considering the different types of
pain, and the treatment efficacy should be evaluated
regularly.ion on the table
him/her to the operating table; older patients should move themselves
ut, elbows, heel, hands, feet)
prior surgery in order to reduce/prevent:
/kg)
f intravenous line, otherwise inhalational anaesthesia. In the latter case,
n foam (e.g. Mepilex®) or a water-based lubricant.
halmologic gel and the eyelids with moistened gauzes
itac®) to fixe all tubes (e.g. endotracheal tube) and catheters
ricant
llowing only the lubricated central portion to be in contact with the skin;
(e.g. Mepilex ®)
ssings under the blood pressure cuff
lar pad
tion for the entire duration of surgery
s and prominent incisors in RDEB* patients who need intubation
ngoscopy in case of difficult intubation
ergence to avoid cutaneous lesions due to irritability
oft and small tubes
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 Pain is acute, chronic and related to procedures (e.g.
bathing, dressing, surgical procedures, etc.).
Psychological pain and anxiety contribute constantly
to worsen organic pain.
 Acute pain is mainly due to newly-onset mucosal
lesions (cornea, oral cavity, oesophagus, anus or
larynx and trachea).
 Chronic pain includes inflammatory, neuropathic
and bone pain.
 The general conditions and nutritional status affect
the severity of chronic pain.
 Evaluation of pain is mandatory and should address
all the above mentioned components. It can be
difficult in particular in children. Pain evaluation
scales and frequency are the same used for non-EB
patients and vary according to the patient age and
on-going procedures.
 An EB expert should examine and listen attentively
to the patient and his family in order to design the
individual therapeutic strategies.
 An early adequate management of the physical pain
is mandatory in order to reduce also the
psychological pain component and to promote
patient compliance.
 An early and regular psychological support for
patients and families can contribute to the global
efficacy of pain management.
 Unfortunately, in some cases, both pharmacological
and psychological management strategies do not
achieve complete pain control.
General measures
Pain related to nursing procedures
 Bathing and dressing should be performed in a
room equipped with all the necessary materials
prepared in advance and close at hand (Figure 1).
Non-pharmacological treatments based on
cognitive-behavioural techniques are essential. A
quiet and relaxing environment is helpful (music,
films, pacifier dipped in glucose solution, etc.). The
caregiver should provide contact, caresses and sweet
words. Hypnosis can be useful in older children and
adults.
 The choice of pharmacological treatment depends
on the patient age, psychological status, type and
severity of pain and planned procedure. The time of
drug administration before the procedure varies
according to the type of drug and route [68-73].
 Topical anaesthetics (xylocaine, lidocaine-prilocaine)
are recommended before the care of painful tense
blisters or wounds and venipuncture. However, thetotal dose should be limited to prevent the risk of
seizures and methemoglobinemia.
 Paracetamol is the first choice for mild pain and
short procedures. In more severe pain and complex
procedures, opioids are indicated (from codeine to
oxycodone and morphine). Opioid side effects
include constipation, pruritus and rarely respiratory
failure. The development of tolerance leads to dose
increase with risk of addiction [70-74].
 Hydroxyzine and midazolam can be associated to
analgesics to reduce anxiety and for short sedation.
More rarely, ketamine is also used, particularly in
children [75,76].
 Meopa® (nitrogen monoxide-oxygen mixture) can be
helpful in most severe pain both in children and adults.
Its use is restricted to the hospital setting and limited
in time.
Chronic pain
 General measures are essential (e.g. music, yoga,
relaxation techniques, hypnosis, etc.). In most cases,
they need to be combined with analgesics.
Paracetamol is usually the first-line treatment,
followed by opioids (codeine, morphine, etc.). Non
steroid anti-inflammatory drugs (NSAID) should be
cautiously administered in patients with chronic/
severe infections.
 A neuropathic pain component can be managed
with pregabalin (Lyrica®) or gabapentin (Neurontin®)
[73]. Tricyclic antidepressants, e.g. amitriptyline, are
an alternative treatment.
 The daily analgesic dose should be distributed over
24 hours and increased before any care procedure.
 Bone pain, usually observed in severe RDEB, is due
to abnormal bone mineralization, in turn related to
poor nutrition, reduced mobility and chronic
inflammation. Therefore, the improvement of
nutritional status and physiotherapy contribute to
reduce pain. Biphosphonates are useful to decrease
bone pain, but their administration can be limited
by perfusion difficulties and side effects (e.g.
mandible osteonecrosis).
Acute pain
 Reassure the patient and his family.
 Administer adequate analgesic therapy (frequently
opioids) or increase the dose of the ongoing
treatment.
 Local anaesthesia may be useful in case of painful
constipation due to anal erosions or fissures.
Botulinum toxin for anal sphincter relaxation may
represent a valid alternative.
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 Acute and chronic pain induce psychological pain
since the first days of life.
 An inadequate pain control during procedures may
cause a vicious circle with a memorization of the
physical pain, and then anticipation and
psychological distress increasing the physical pain at
each procedure. Relaxation techniques,
psychological support and pharmacological
treatment should be provided.
 Psychological support should be reinforced during
adolescence. A latent depression is not exceptional
in the most severe forms and appropriate treatments
have to be administered.
Nutritional aspects
Growth and nutritional condition are major outcomes in
EB patient care. Nutrition is often a real challenge. Blisters
and erosions affecting oropharynx and oesophagus cause
pain and dysphagia, followed by microstomia, ankyloglossia
and tooth decay in severe RDEB. Altogether these manifes-
tations contribute to reduce oral intake. Recurrent
blistering can also lead to strictures and even complete
oesophageal obstruction which are usually managed by
endoscopic dilation [77-79].
On the other hand, protein-calorie and micronutrient
needs are increased by (i) accelerated skin turn-over, (ii)
blood and protein losses through skin wounds, (iii)
recurrent infections, and (iv) chronic inflammation.
Micronutrient deficiencies (iron, zinc, selenium, vita-
mins, etc.) can lead to severe complications. Iron, folate
and vitamin B12 deficiencies contribute to multifactorial
anemia typical of severe RDEB and JEB. Other nutrient
deficiencies (carnitine, selenium) might play a role in in-
ducing cardiomyopathy. In addition, an insufficient fluid
and fibre intake frequently causes constipation, which
can induce painful defecation (anal fissures). Overall, nu-
tritional compromise is more important in generalized
forms of RDEB and JEB [80-82].
Unfortunately, an improvement of nutrition in severe
EB subtypes is usually not associated with a significant
amelioration in wound healing rates. Nevertheless, an
appropriate nutritional management is necessary since
infancy also to promote pubertal development.
General principles
 The evaluation of patient growth, performed
according to international standards (weight for
length < 2 years; body mass index > 2 years), can be
hampered by fixed contractures.
 The nutritional support should start early, especially
in severe generalized subtypes. Dietetic advices, aimed to increase energy and
protein content of oral food, should be addressed
continuously to patients and their families.
 All factors affecting the quality of nutrition need
careful management and follow-up: trauma related
to hard food, dental caries and periodontal
inflammation, gastro-oesophageal reflux,
oesophageal strictures, inflammatory bowel disease,
anal fissures and constipation, etc.
General measures
 Proteins and energy
Conventional dietetic approaches using oral high-
energy and high-protein semi-liquid supplements rarely
provide sustained improvement of dietary intake in se-
vere EB forms. Consequently, children who survive with-
out nutritional support become thin and short adults. A
specific Tool to Help Identify Nutritional Compromise
(THINC) in EB has been designed. The suggested
nutritional requirements reach about 100-150% of the
recommendations for healthy age- and gender-matched
children for energy and 115-200% for proteins [81].
 Micronutrient requirements [81-87]
Evaluation of iron needs is frequently hampered by
chronic inflammation. Daily intake of iron is recom-
mended in case of hypochromic microcytic anemia;
however it is often associated with gastric irritation, diar-
rhea or constipation. If oral supplementation is not tol-
erated and/or insufficient, intravenous administration
(Venofer®, Ferinject®) should be considered and its fre-
quency adapted to each patient. The use of erythro-
poietin or darbepoetin alfa in combination with iron
supplementation has been proposed [85]. Vitamin re-
quirements should be evaluated considering the disease
type and patient age. In more severe forms, vitamin (A,
C, D, E) levels should be checked at least once a year.
Vitamin C supplementation is useful to enhance iron ab-
sorption. Vitamin D and calcium supplementation are
needed to prevent/treat osteoporosis. Zinc, carnitine and
selenium levels should be evaluated at least once a year
in the most severe forms [88].
 Nutritional procedures: nasogastric and gastrostomy
feeding
Nasogatric feeding can induce internal friction, irrita-
tion of nostrils and hypopharynx or oesophageal ero-
sions. Therefore it should be used only for short periods
in presence of severe oral cavity and pharyngeal blister-
ing. The tube should be soft and of small size.
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tolerated and to improve patient nutritional outcome,
growth and puberty. It should be performed in patients
unable to feed orally (e.g. very severe and chronic oral
lesions or oesophageal strictures not susceptible to dila-
tion treatment) and/or presenting loss in weight and
height of at least 1 standard deviation compared with
their best growth level, despite regular nutritional advice.
Starting GTF before malnutrition onset also reduces the
problems linked to the choice of the button device and
to the insertion site dehiscence [89-91]. A regular sur-
veillance is necessary in order to prevent and/or early
treat the possible local complications (chronic wound
and infection).
The rhythm and rate of GTF delivery, volume, energy
intake and formula concentration should be adapted to
individual needs and tolerance and to patient and family
lifestyle. The use of anti-secretory and anti-acid drugs (e.
g. ranitidine or proton pump inhibitors) is recom-
mended to treat gastro-oesophageal reflux and also to
prevent skin damage due to gastric acid leakage at gas-
trostomy site [91]. GTF also easies the supply of micro-
nutrients (iron, zinc, selenium, vitamins), nutritional
supplements or drugs.
Oral feeding and swallowing skills should be continu-
ously encouraged while using GTF. The patient should
participate to “familial life” and familial meals. In all
cases, a psychological support is essential. After the
achievement of puberty development gastrostomy can
be removed, provided a sufficient oral nutrition and ab-
sence of intractable oesophageal strictures. Unfortu-
nately in JEB-Herlitz, GTF is not successful and thus not
recommended in the context of palliative care [92].
Physical therapy and rehabilitation
Physical and occupational therapy must be started early
in life in particular in EBS with muscular dystrophy, gen-
eralized RDEB and JEB subtypes. The continuing work
on muscles and joints delays contractures and deform-
ities, improves functional mobility, enhances patient au-
tonomy and, ultimately, promotes social inclusion. Static
(preventive) and dynamic (corrective) orthosis, directed
therapeutic exercises and recreational activities are
powerful tools. Some forms of physical medicine, such
as hydrotherapy, are also useful [93,94].
Early diagnosis of squamous cell carcinoma (SCC)
SCC represents one of the major complications of EB, in
particular generalized RDEB subtypes and, less fre-
quently, generalized non-Herlitz JEB [5,12]. It occurs
more often from the third-fourth decade of life. SCC
usually arise in areas of chronic wounds and scars. The
clinical presentation is frequently atypical with warty or
ulcerated appearance. An early diagnosis is mandatoryand literature data highlight that a diagnosis delay im-
plies a poor prognosis.
In order to ensure an early diagnosis, it is necessary to
perform [95]:
 whole-body physical examination, including the
scalp, oral mucosa and genital area, every 6 months
in RDEB and adult JEB patients;
 more frequent follow-up in presence of chronic
hyperkeratotic or warty wounds;
 multiple excisional biopsies in case of crusted-warty
skin lesions or chronic wounds unresponsive to
proper treatments;
 early and wide excision of the lesion in case of
histologically confirmed carcinoma.
Management of intercurrent or associated cutaneous
diseases
A few reports describe cutaneous infectious diseases
occurring in EB patients, and even fewer data exist about
associated chronic inflammatory diseases (psoriasis,
atopic dermatitis, etc.) [96-99].
Skin diseases, when manifesting in EB patients, can:
 represent a diagnostic challenge due to atypical
presentation (impetigo, scabies, etc.);
 worsen EB course, due to the development of
pruritus and risk of infection (e.g. atopic dermatitis,
scabies, VZV infection, impetigo, etc.);
 need an adapted management which should take into
account the presence of EB lesions and the increased
risk of percutaneous absorption. Some topical products
may indeed cause irritation and toxicity (e.g. topical
treatment for cutaneous parasitic infestations, such as
benzyl benzoate, permethryne).
When dealing with these intercurrent/associated dis-
eases, the principles for diagnosis and therapy are:
 Pruritus onset/worsening in EB patients should
foster investigation for parasitic infestation such as
scabies and lice.
 Pruritus in associated cutaneous diseases should be
treated as described for pruritus in EB patients
(Table 6) in order to prevent worsening of EB
lesions.
 Ivermectin represents a valid alternative to standard
topical treatment for parasitic infestations in EB
patients with generalized disease [96,97].
Therapeutic patient education
Therapeutic patient education, as defined by the World
Health Organization (WHO), is a continuous process of
patient-centered medical care, enabling patients affected
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their illness [100]. Patient education has been shown to
also contribute to prevent complications and to improve
quality of life (QoL).
Despite the lack of controlled studies, patient educa-
tion is unanimously considered extremely important also
for EB patients and their caregivers.
Table 8 summarizes the principles and measures of
therapeutic patient education applied to EB.
Care of disease burden
EB has a major impact on the QoL of the patient and
his family, starting since birth when the baby diversity
is immediately perceived by the parents and the
transmitted notion of skin fragility can hamper the
development of normal affective relationships within
the family. Isolation, fear or insecurity about infant
care, breastfeeding, where to go for help, role adjust-
ment, fatigue, relationship with siblings or partners,
body image, nutrition, and the need for peer support - all
must be dealt with [101-107].
Specific problems can then manifest at every age, they
range from the patient perception of his diversity to dis-
ease limitations in daily life and challenges related to so-
cial integration. Coping with continuous pain and
consciousness of disease worsening represent major
challenges for these patients and their families, in par-
ticular in severe disease forms.
General principles
 Whenever possible, the transfer of the newborn
to the centre of expertise should be performed
when also the mother is able to move, avoiding
disruption of the close parent-infant relationship
or even the infant refusal.
 A gradual and multistep delivery of information on
diagnosis and prognosis can reduce theTable 8 Patient education in epidermolysis bullosa: principles
Principles • Should be addressed to the patient, his/her family and caregi
• Should be delivered individually or in group
• Should be adapted to the EB subtype, patient age, socio-cultu
• Should be delivered by specialized nurses with the support o
• Should be performed orally and gradually, complemented by th
Contents • Should at first clearly communicate the diagnosis, disease cou
• Should give clear explanations on the need of an adapted ge
• Should train the patient and his/her family/caregivers on the
• Should educate the patient and his/her family/caregivers to e
wounds, and to consequently request a rapid evaluation by a
• Should provide training on the life style in order to prevent dpsychological trauma. Particular caution should be
taken to avoid culpability feelings in the parents.
 The involvement of both parents in the education
process may facilitate their coping with the disease,
reduce couple difficulties and reinforce their
relationship.
 The parents should be accompanied in the
educational process of the affected child, at the same
time ensuring that the child progressively acquires
as much autonomy as possible.
 The participation of the entire family can reduce the
risk that non affected siblings feel neglected by the
parents.
 A psychological support to the patient and his
family is frequently needed and should be integrated
in the multidisciplinary management process.
 Monitoring of the emotional status of the patient
and/or his family and early diagnose psychological
distress require yearly appointments with a
psychologist even in absence of specific symptoms.
 Specific instruments should be used for evaluation
of psychological status and QoL [108-110].
 The psychologist should be involved early when the
newborn parents manifest signs of persisting
distress.
 Indications to the provision of psychological and
psychotherapeutic support to the patient and family
members are summarized in Table 9.
Continuity of care
A well-organized and structured continuity of care is im-
portant in EB like in all chronic and rare diseases. Fol-
lowing hospital discharge, EB patients require social
support and medical assistance for EB-related and non-
related problems. The center of expertise stays as the
main structure offering specialized care to EB patients
and, at the same time, should ensure an adequate liaison
with the community healthcare system. Public healthand contents
vers
ral milieu and compliance
f the members of the multidisciplinary team and the psychologist
e release of information sheets for the patient and his/her family/caregivers
rse and complications
netic counselling
management of cutaneous and extracutaneous manifestations
arly recognize infection signs and atypical aspects of the chronic
dermatologist
isease worsening
Table 9 Indications to psychological or psychotherapeutic support to the family member(s) and patient
Family members • Fear to breastfeed or handle the newborn and/or infant refusal
• Lack of self-confidence or inadequacy feeling in coping with the disease
• Anxiety to be left alone with the disease
• Depression or disease refusal by one the two parents
• Altered relationship of the couple (e.g. lack of interest in carrying out activities as a couple, loss of intimacy, negative impact
on sexuality, etc.)
• Culpability feelings and inability to take care of the non-affected children
• Discomfort feelings or depression of the siblings
Patient • Stress or depression related to the visibility of disease manifestations and the feeling of being different
• Chronic pain exacerbated by daily care procedures
• Chronic itching resistant to therapy
• Stress or depression due to limitations in daily activities and social life
• Lack of compliance and adherence to treatment, particularly in
• Adolescence and adulthood
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greatly country by country and even within the same
country region by region. Nevertheless, some general
rules can be drawn. At hospital discharge:
 a detailed referral form must be delivered and
addressed to the primary care physician
(pediatrician or general practitioner). It must report
the diagnosis and the care given during
hospitalization, describe the treatment plan for
patient home care, the follow-up schedule and
report the contact details of the EB team coordinator
or his/her delegate from the center of expertise (e.g.
specialized nurse) and, whenever available, of
hotlines/call centres for emergency or urgent
professional information;
 whenever foreseen by national laws, a certificate
stating the diagnosis and a treatment plan must be
addressed to the relevant public health authority in
order to ensure free-of-charge care and provision of
needed drugs, dressings and devices;
 depending on the national laws, ad hoc certificates
must also be addressed to the public health service
in order to guarantee homecare by specialized
nurses, and if necessary also psychological support,
physical therapy, occupational therapy, assistance by
social workers, etc.;
 in countries where specialized EB nurses are not
available, ad hoc training of the community health
nurses is recommended;
 information sheets should be provided to the family/
caregiver (relatives, friends, teachers, colleagues,
etc.) in order to promote an adequate relationship
with the patient, to explain the impact of the disease
on daily activities and QoL (education, work,
household chores, life management); information about the opportunity to get in touch
with the patient association, if present in the
country, should be released as detailed below.
The relationship with the patient association
In most countries, DebRA is the EB patient association. All
national DebRA belong to an umbrella organization known
as DebRA International (www.debra-international.org).
 Patients should be informed about the presence of
the patient association in their country and the
interest to become a member.
 Patient associations contribute to improve patient
access to information, reference centres, and social
services.
 They also facilitate contact between patients and
sharing experience regarding daily life.
 In some countries, they provide financial support
and/or fund nurse home care and/or organize
vacations for patients and families.
 Finally, they can contribute to promote professional
training and research.
Summaries
The optimization of EB patient healthcare requires the
implementation of a wide range of measures. Towards
this goal, the establishment in each country of expertise
centres, which guarantee a multidisciplinary care, is es-
sential. Equally important is the sharing of standards of
care among expertise centres. The present recommenda-
tions should easy this process, support clinicians in-
volved in EB care and, overall, contribute to improved
patient care and QoL. Nevertheless, multicentre trials
are needed, in particular to standardize interventions in
wound care, itch and pain management, treatment of
pseudosyndactyly and prevention and therapy of
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http://www.ojrd.com/content/9/1/76squamous cell carcinoma [38]. Finally, recent progress in
the development of different gene, protein and cell ther-
apy approaches open new perspectives for the treatment
of these patients. In addition to the pilot study published
by Mavilio and coworkers showing the feasibility of ex-
vivo gene therapy in generalized non-Herlitz JEB [111],
the results of clinical trials based on the use of (i) allo-
genic fibroblasts for local RDEB wound care [112,113]
and (ii) allogenic hematopoietic stem cell/mesenchymal
cell transplantation for severe RDEB forms [114] have
been recently described. In particular hematopoietic
stem cells transplantation has been reported to result in
significant disease improvement, but not cure, in the
majority of treated patients and further studies are on-
going to minimize the severe risks associated with trans-
plantation procedure and to optimize the treatment
protocol [114]. These results indicate that effective and
specific EB treatments able to block disease progression
are likely to become available in the medium term.
Consent
Written informed consent was obtained from the partic-
ipants for publication of this review and accompanying
images, with additional parental written consent from
those under 18 years of age.
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